A study published in Cancer Discovery, the newest journal of the American Association for Cancer Research, debuting here at the AACR 102nd Annual Meeting 2011, held April 2-6, showed how evaluating the immune response in the tumor microenvironment may help researchers better target therapy in breast cancer.
Evidence continues to build that telomeres, cell endings that fray as we age, are affected by stress and are predictive of cancer risk. Scientists will present new groundbreaking research in this area of study at an AACR 102nd Annual Meeting 2011 press conference held on Sunday, April 2 at 2:00 p.m. ET in room W313 of the Orange County Convention Center.
Using new genetic information, scientists have linked a commonly found human genetic variant with both longer telomeres and reduced risk of bladder cancer, according to findings presented at the AACR 102nd Annual Meeting 2011, held April 2-6, and simultaneously published in Cancer Prevention Research, a journal of the American Association for Cancer Research.
Results of a study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6, lend credence to the idea that improving quality of life affects stress-related biological markers and possibly the health of people with cancer.
The American Association for Cancer Research Annual Meeting continues to be a showcase for the most cutting edge science in cancer, and this year’s meeting, held here April 2-6, will include an increased focus on clinical trials that will impact patient care.
A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
Scientists are continuing their work on the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination trial — known more commonly as the BATTLE trial — and presented updated results at the AACR 102nd Annual Meeting 2011, held here April 2-6.
The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.
Scientists have identified a biomarker for measuring the success of lung cancer chemoprevention, an emerging frontier in the fight against this disease that has long been stymied by a lack of measureable outcomes. These study results were presented at the AACR 102nd Annual Meeting 2011, held April 2-6.
In one of the largest cancer genomics investigations reported to date, scientists have sequenced the whole genomes of tumors from 50 breast cancer patients and compared them to the matched DNA of the same patients’ healthy cells. This comparison allowed researchers to find mutations that only occurred in the cancer cells.
1) Test conducted in the non-cancerous part of the prostate; 2) May aid in localization of cancer lesion within the prostate gland.
The AACR would like to congratulate its newest grant recipients at the AACR 102nd Annual Meeting 2011, held April 2-6.
Scientific breakthroughs in personalized medicine, diagnosis and prevention of cancer will take center stage when more than 18,000 people from around the world gather at the Orange County Convention Center in Orlando, Fla., from April 2-6 for the AACR 102nd Annual Meeting 2011.
Arthur D. Levinson, Ph.D., chairman and former CEO of Genentech Inc., will receive the Fifth Annual American Association for Cancer Research Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research at the AACR 102nd Annual Meeting 2011, held April 2-6.
Susan Band Horwitz, Ph.D., will receive the Eighth Annual AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel (Taxol), which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas. Her work has also contributed to the understanding of how microtubules function in normal and malignant cells and why stabilization of microtubules is a promising target for drug discovery.
The Fifth Annual AACR Team Science Award will be given to a team of internationally renowned molecular biologists, epidemiologists, biostatisticians and clinicians from Fred Hutchinson Cancer Research Center and University of Washington who have worked together on human papillomavirus (HPV) for more than 20 years.
The American Association for Cancer Research will present the Honorable John Edward Porter (R-Ill.) with the 2011 AACR Award for Distinguished Service and Global Impact in Cancer and Biomedical Research. Porter, chairman of Research!America and acting chair of the Foundation for the National Institutes of Health (NIH), was chosen for this special award because of his significant and sustained contributions to cancer and biomedical research, including his leadership of the effort to double the budget of the NIH.
Pier Paolo Pandolfi, M.D., Ph.D., is the recipient of the 2011 Pezcoller Foundation-AACR International Award for Cancer Research for his outstanding work in the field of cancer genetics and mouse models for cancer. This work has contributed to new therapies for treating cancers.
Yosef Shiloh, Ph.D., a David and Inez Myers professor in cancer research in the department of Human Molecular Genetics and Biochemistry in the Sackler School of Medicine at Tel Aviv University, Israel, will receive the 51st Annual AACR G.H.A. Clowes Memorial Award for his studies of the cellular DNA damage response and the rare genomic instability syndrome ataxia-telangiectasia (A-T).
The American Association for Cancer Research will recognize leading cancer researchers whose work has significantly contributed to progress in the fight against cancer at the AACR 102nd Annual Meeting 2011. Each recipient will present an educational lecture at the meeting, which will be held April 2-6 at the Orange County Convention Center.
The Pancreatic Cancer Action Network and the American Association for Cancer Research awarded 10 grants to outstanding scientists throughout the country, supporting their innovative research in the field of pancreatic cancer. This year’s total funding level of nearly $3 million represents the largest annual disbursement since the Pancreatic Cancer Action Network introduced the program in 2003. The recipients will be honored at a recognition event scheduled during the AACR 102nd Annual Meeting 2011, held April 2-6, at the Orange County Convention Center in Orlando, Fla.
The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Jennifer M. Bailey, Ph.D., and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic Cancer Action Network–AACR Pathway to Leadership Grants. These grants, each totaling $600,000 over five years, will be formally awarded at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research is pleased to announce the recipients of the 2011 Caring for Carcinoid Foundation-AACR Grants for Carcinoid Tumor and Pancreatic Neuroendocrine Tumor Research and the 2011 Raymond and Beverly Sackler AACR Fellowships for Ileal Carcinoid Tumor Research.
The American Association for Cancer Research and the Kirk A. and Dorothy P. Landon Foundation will present three INNOVATOR Awards at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research is awarding 50 Minority Scholar in Cancer Research Awards at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research will recognize leaders in the minority cancer community with the Minority-Serving Institution Faculty Scholars in Cancer Research Awards. The 36 recipients will be honored at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research will recognize 27 recipients of the AACR-Thomas J. Bardos Science Education Award for Undergraduate Students at the AACR 102nd Annual Meeting 2011, held here from April 2 to 6.
The members of the American Association for Cancer Research have elected Frank McCormick, Ph.D., D.Sc. (hon.), as their president-elect. McCormick is the director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. He holds the E. Dixon Heise distinguished professorship in oncology and the David A. Wood distinguished professorship of tumor biology and cancer research at UCSF. Additionally, he is the associate dean of the UCSF School of Medicine and a distinguished professor in residence in the department of microbiology and immunology as well as in the department of biochemistry and biophysics.
The members of the American Association for Cancer Research have elected Frank McCormick, Ph.D., D.Sc. (hon.), as their president-elect. McCormick is the director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. He holds the E. Dixon Heise distinguished professorship in oncology and the David A. Wood distinguished professorship of tumor biology and cancer research at UCSF. Additionally, he is the associate dean of the UCSF School of Medicine and a distinguished professor in residence in the department of microbiology and immunology as well as in the department of biochemistry and biophysics.
Since the passage of the Family Smoking Prevention and Tobacco Control Act in 2009, the U.S. Food and Drug Administration (FDA) has met the ambitious implementation deadlines set forth in the law, the agency said Wednesday at a congressional briefing hosted by the American Association for Cancer Research.
In 2009, a historic new law granted the U.S. Food and Drug Administration (FDA) authority to regulate the manufacturing, marketing and sale of tobacco products. The FDA will give an update on the implementation of the Family Smoking Prevention and Tobacco Control Act at a congressional briefing hosted by the American Association for Cancer Research on Wednesday, March 16.
The Pancreatic Cancer Action Network and the American Association for Cancer Research have awarded Jennifer M. Bailey, Ph.D., and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic Cancer Action Network – AACR Pathway to Leadership Grants. These grants, each totaling $600,000 over five years, will be formally awarded at the AACR 102nd Annual Meeting 2011, held April 2-6.
The American Association for Cancer Research will hold its 102nd Annual Meeting at the Orange County Convention Center from April 2-6, 2011.
1) Obese women had a 35 percent increased risk of breast cancer; 2) Risk was similar to increase in estrogen receptor-positive cancer; 3) Obesity may increase risk through mechanisms other than estrogen.
Susan Band Horwitz, Ph.D., will receive the Eighth AACR Award for Lifetime Achievement in Cancer Research. Horwitz conducted pioneering research by discovering the mechanism of action of the chemotherapeutic drug paclitaxel (Taxol), which prompted the development of this drug as an important therapy for many common solid tumors, including ovarian, breast, and lung carcinomas. Her work has also contributed to the understanding of how microtubules function in normal and malignant cells and why stabilization of microtubules is a promising target for drug discovery.
The Fifth Annual AACR Team Science Award will be given to a team of internationally renowned molecular biologists, epidemiologists, biostatisticians and clinicians from Fred Hutchinson Cancer Research Center and University of Washington who have worked together on human papillomavirus (HPV) for more than 20 years.
1) Participants with low- and high-grade gliomas were less likely to report any allergy; 2) Antihistamine use, independent of allergy status, may not influence glioma risk; 3) Age when diagnosed and years since diagnosis of allergies were not associated with glioma risk.
Yosef Shiloh, Ph.D., a David and Inez Myers professor in cancer research in the department of human molecular genetics and biochemistry in the Sackler School of Medicine at Tel Aviv University, Israel, will receive the 51st Annual AACR G.H.A. Clowes Memorial Award for his studies of the cellular DNA damage response and the rare genomic instability syndrome ataxia-telangiectasia (A-T).
The AACR 102nd Annual Meeting 2011 attracts world leaders in cancer research and treatment, including clinical oncologists, basic scientists, translational researchers and epidemiologists, who are working to improve prevention, diagnosis and patient care with the ultimate goal of eradicating cancer
Pier Paolo Pandolfi, M.D., Ph.D., is the recipient of the 2011 Pezcoller Foundation-AACR International Award for Cancer Research for his outstanding work in the field of cancer genetics and mouse models for cancer. This work has contributed to new therapies for treating cancers.
1) Head and neck cancer accounts for 650,000 new cancer cases each year; 2) Data provide insight into novel mechanisms underlying head and neck cancer; 3) Potential new targets for chemoprevention identified.
Stand Up To Cancer (SU2C), the charitable initiative generating public awareness of and support for ground-breaking research aimed at getting new cancer treatments to patients in an accelerated timeframe, has acquired the TV and film rights to The Emperor of All Maladies: A Biography of Cancer, written by Siddhartha Mukherjee and published by Scribner in November, 2010. The book traces the history, or biography, of the disease from its first appearance thousands of years ago through the Nixon era War on Cancer 40 years ago to today’s promising new directions in cancer medicine.
1) Early research suggests that the immune system can affect angiogenesis; 2) Manipulation of angiogenesis is a key therapeutic strategy for cancer.
1) Use of aromatase inhibitors in early-stage breast cancer patients affected. 2) Older women more likely to discontinue early because of high co-payments. 3) Primary care physician involvement, quantity of other prescriptions affect use.
1) Weight of babies exposed to intrauterine chemotherapy tended to be higher; 2) More malformations were found, regardless of treatment; 3) Multidisciplinary team should be part of pregnant patient’s cancer management.
1) Possible new treatment option for early HER2-negative breast cancer; 2) Safety data, published earlier this year, indicated bevacizumab was feasible; 3) Data on response and surgical outcomes to be presented at symposium.
1) High-dose chemotherapy and autologous stem cell transplantation is effective therapy; 2) Therapy may release cancer stem-like cells from bone marrow; 3) Patients who had low circulating tumor cells did well.
1) Predictive value independent of serum tumor markers. 2) CTCs are independent prognostic marker for metastatic disease.
1) Denosumab may be a safe, effective alternative to zoledronic acid; 2) Drug is easy to administer via subcutaneous injection; 3) Dose adjustments or renal monitoring is not required.
1) Blood was tested after surgery and before chemotherapy. 2) Risk was apparent with just one CTC in the blood. 3) More individualized treatment approaches might be possible based on CTC characterization.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right